Search
Molnupiravir
go.drugbank.com/drugs/DB15661Investigational[A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to
Xylazine
go.drugbank.com/drugs/DB11477InvestigationalVet approved[L42680] The intentional and unintentional use of xylazine is a cause for concern due to its side effects.
NM-702
go.drugbank.com/drugs/DB05505InvestigationalIt is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalHigher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesCatridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen.
Droloxifene
go.drugbank.com/drugs/DB15641ExperimentalDroloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity.[L34184]
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigational[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: ATORVASTATINA P-CARE, Dengue KillNabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalTetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnBinding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRauwolfia serpentina root
go.drugbank.com/drugs/DB09363InvestigationalThis product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630].